Anticoagulants Market Size to Expand USD 70 Billion by 2030

Published Date : 09 Sep 2022

The global anticoagulants market size was reached at USD 32 billion in 2021 and is expected to expand around USD 70 billion by 2030 with a CAGR of 9.09% from 2022 to 2030.

At this time, a number of dangerous and serious diseases have shown increasing prevalence in the global context. One of the dangerous diseases is cardiovascular disease, a disorder with high prevalence around the world, especially due to modern lifestyle changes. In general, cardiovascular disorders are treated with a set of cardiovascular drugs, one of the important components of which is a blood thinner. Without the presence of effective blood thinners, blood clots are more likely to form and lead to heart attacks and other serious conditions.

In the current context of the global anticoagulants market, several factors are giving great impetus to the development of these drugs. There is growing awareness about heart health and the possible negative consequences or effects of ignoring it.

The growth of the global anticoagulants market includes the introduction of new types of treatments known as oral approaches blood thinners (NOACs).

Report Highlights

  • By indicated disease, the pulmonary embolism segment has made up 75% revenue share in 2021.
  • By administration, oral anticoagulants segment holds the largest market share in the global market. However, injectable anticoagulants is expected to be the fastest growing segment during the forecast period.
  • On the basis of application, the atrial fibrillation & heart attack segments accounted for the highest market share and is anticipated to retain its dominance during the forecast period. 
  • By distribution channel, the hospital pharmacy segment has garnered 50% revenue share in 2021.
  • By region, North America holds the largest market share of around 58% in 2021. However, Asia-Pacific is expected to be the fastest growing market for the anticoagulants.

What is the regional impact in the anticoagulants market?

  • North America accounted for the largest market share in the year 2021 in anticoagulants industry and is expected to restrain dominant in the global market during the forecast period in terms of value sales. High rates of cardiovascular diseases requiring anticoagulant treatment, coupled with regional new product launches, is likely to fuel the market growth in this region.
  • Asia Pacific is predicted to witness high growth rate during the anticoagulants market forecast period owing to the growing disposable income throughout the region, rising consumer attention towards the cardiovascular illnesses. Increasing incidence of cardiovascular diseases from the key countries in this region such as China, India and others, adoption of advance anticoagulants and the growing popularity of cardiovascular disease as the main reason of growing mortality rate is likewise expected to offer lucrative opportunities for fueling the demand the blood thinners in the market. Thus, contributing towards the overall growth of the market in this region.
  • Furthermore, Europe is anticipated to witness considerable growth in the market owing to  the rising number of death due to cardiovascular disease, which is encouraging better adoption of blood thinning medications in this region. 
  • The Latin America marketplace for anticoagulant pills is expected to go through sturdy increase because of the growing incidence of cardiovascular illnesses which include coronary heart attacks. The Middle East and Africa is predicted to witness consistent growth rate in the market during the forecast period owing to the growing incidence of cardiovascular illnesses and extra adoption of superior anticoagulant pills.

Scope of the Report

Report Coverage Details
Market Size in 2030 USD 70 Billion
Growth Rate from 2022 to 2030 CAGR of 9.09%
Largest Market North America
By Indication of disease
  • Pulmonary Embolism (PE)
  • Deep Vein Thrombosis (DVT)
  • Atrial Fibrillation
  • Heart Attacks
  • Others
By Administration Route
  • Oral
  • Injectable
By Drug Class
  • NOACs
  • Eliquis
  • Bevyxxa
  • Xarelto
  • Savaysa & lixiana
  • Pradaxa
  • Heparin & LMWH
  • Vitamin K Antagonist
  • Others 
By Distribution Channel 
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacy
  • Others
By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • MEA


Market Dynamics


Rising product awareness and innovation to augment market growth.

One of the major drivers for the growth of the market is the increased awareness of cardiovascular health and the corresponding increase in release therapy. Cardiovascular therapy involves a multifaceted approach that may lead to the use of several types’ medications, but blood thinners are an essential part of this treatment regimen. Moreover, several key market leaders have introduced some anticoagulants, meeting an important therapeutic need for the prevention of blood clots. 


Rising demand for advance and effective drugs to fuel the market

The high worldwide prevalence of cardiovascular disease (CVD) and the growing demand for more efficient blood thinner products to drive growth of the market in terms of value sales. Anticoagulants have been the subject of major innovations in research and development since their introduction to the public. Some novels Therapeutic agents such as new oral anticoagulants (NACOs) have been introduced to the world market with great success. Global The current market scenario includes two major anticoagulants: Eliquis and Xarelto. Greater presence of generics and other early launches of generic anticoagulants can have a negative impact on the market. But the nature of cardiovascular disease (CVD) has made it almost impossible to cure and the increase in this ratio has further worsens the treatment outlook for the patient. This has some unmet therapeutic need in the market and is anticipated to be one of the major driving factors in the market.

Key players

  • Johnson & Johnson
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim GmbH
  • Aspen Holdings
  • Pfizer Inc.
  • Daiichi Sankyo Company
  • GlaxoSmithKline Plc
  • Sanofi S.A.
  • Portola Pharmaceuticals

Full Report is Ready | Buy this Research Report@

You can place an order or ask any questions, please feel free to contact at | +1 9197 992 333